RXRX stock forecast, quote, news & analysis
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company... Show more
Recursion Pharmaceuticals (RXRX) Stock Analysis: AI Partnerships Fuel Biotech Momentum
Key Takeaways
- RXRX shares have shown volatility in recent weeks, trading well below 52-week highs amid broader market pressures.
- Expanded partnership with Citeline enhances AI-driven clinical trial capabilities, boosting platform potential.
- New Chief Medical Officer appointment signals leadership strengthening for pipeline advancement.
- Upcoming Q1 2026 earnings on May 4 could provide pipeline updates and financial clarity.
- Cash runway extends to 2028, supporting AI investments despite ongoing losses.
- Analyst consensus leans toward Hold/Buy with average price targets around $6.00.
Current Market Snapshot
Recursion Pharmaceuticals (RXRX) has navigated choppy waters in recent trading sessions, with shares fluctuating amid biotech sector headwinds and broader risk-off sentiment. The stock hovers around levels significantly off its 52-week highs, reflecting investor caution over clinical timelines and cash burn in the AI-drug discovery space. Volume has varied, with spikes during news events, while the high short interest underscores skepticism. Despite occasional upticks from positive platform developments, underperformance relative to market gains highlights sensitivity to macroeconomic pressures and sector rotations. Fundamentals remain tied to pipeline progress and partnership milestones.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that collectively trade thousands of tickers across stocks, ETFs, and crypto. These virtual agents employ diverse strategies like swing trading on dips, trend-following in small caps, multi-agent portfolios in semiconductors or gold miners, double-agent long/short pairs, and volatility plays on leveraged ETFs. Timeframes range from 5-minute to 60-minute signals, with hold durations of 1 to 55 days. Standout stats include annualized returns up to 167.82%, win rates of 53.91% to 87.72%, profit factors from 1.50 to 11.70, and profit-to-drawdown ratios reaching 22.13. Ideal for current conditions, these bots offer risk-managed signals adaptable to volatile markets. Explore the curated selection to align with your trading style.
Recent Developments Driving RXRX Price Action
In the past 30 days, Recursion Pharmaceuticals (RXRX) experienced several catalysts that shaped its price trajectory, blending operational positives with sentiment challenges. A key highlight was the expansion of its partnership with Citeline, announced around mid-April, to integrate real-world clinical trial data into Recursion’s AI-powered ClinTech platform. This move enhances the Recursion OS (operating system) by incorporating phenomics, chemistry from the Exscientia merger, and trial data analytics, aiming to accelerate drug discovery and improve trial success rates. Headlines emphasized its potential as a "game changer" for investors, yet shares dipped despite market gains, closing lower on multiple sessions (e.g., down 2%+ amid broader upticks).
Leadership changes added to the narrative: On March 25, Recursion named Vicki Goodman, M.D., as incoming Chief Medical Officer (CMO), effective April 6, succeeding David Mauro. Goodman’s oncology expertise aligns with key pipeline assets, signaling a focus on clinical execution. However, insider sales tempered optimism—on April 8, director Blake Borgeson filed to sell 30,000 Class A shares via Form 144, following earlier March transactions by executives like Najat Khan. Such activity often pressures sentiment in growth-stage biotechs.
On April 7, the company announced participation in the 25th Annual Needham Virtual Healthcare Conference, setting the stage for management updates. This came amid anticipation for Q1 2026 earnings on May 4, with consensus expecting revenue of $17.46 million (up sequentially) and EPS of -$0.28. Prior Q4 2025 results (February 25) beat EPS estimates (-$0.21 vs. -$0.28), but widened losses and high cash burn ($533 million runway to 2028) kept focus on efficiency.
Price action reflected mixed flows: Shares underperformed benchmarks, dropping 16.5% post-Q4 earnings through recent weeks, with Zacks noting steeper declines than the market on April 9, 16, and 20. High short interest (37% of float as of March 31) amplified volatility, exacerbated by broad selloffs. Analyst commentary remained steady—April 14 coverage reiterated healthcare sector insights—while targets held around $6.00 (e.g., BofA Securities). Overall, positives from AI partnerships and leadership were offset by insider moves and macro caution, keeping RXRX range-bound.
2026 Outlook and Key Factors to Monitor
As Recursion Pharmaceuticals advances through 2026, investors should track AI platform maturation and clinical milestones. Key themes include partnerships with Sanofi and Roche, targeting inflows of $100 million by year-end, alongside internal pipeline readouts in oncology and rare diseases. The merged Exscientia capabilities promise streamlined chemistry and trial optimization via ClinTech, with cost reductions extending cash runway into 2028. Revenue consensus projects $85 million growth, driven by collaboration milestones and platform licensing.
Risks encompass clinical setbacks, regulatory hurdles for AI-derived candidates, and competition in computational biology. Opportunities lie in data flywheel effects from 65 petabytes of multimodal data, potential FDA nods for first-in-class assets, and expanding pharma deals. Macro factors like interest rates and biotech funding will influence valuation. Monitor Q1 earnings for pipeline prioritization, R&D spend, and guidance updates to gauge strategic focus amid high burn rates (net loss expected to narrow gradually).
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RXRX's RSI Oscillator leaves overbought zone
The 10-day RSI Indicator for RXRX moved out of overbought territory on June 02, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
RXRX moved below its 50-day moving average on June 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RXRX broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RXRX entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for RXRX crossed bullishly above the 50-day moving average on June 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.569) is normal, around the industry mean (18.049). P/E Ratio (0.000) is within average values for comparable stocks, (35.837). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.672). RXRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (22.075) is also within normal values, averaging (355.556).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RXRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology